-
Inhalation Technology for the 21st Century Innovative A unique portable pneumatic porous medium based soft mist nebulizer / inhaler.
-
Inhalation Technology for the 21st Century Maintenance Free Zero maintenance "plug and play"
disposable cartridge containing medication reservoir and aerosolizing element. -
Inhalation Technology for the 21st Century Versatility and Optimal Delivery The system functions as either inhaler or nebulizer, each capable of generating “soft mist” aerosols with low MMAD (below 2 microns) and high fine particle fraction.
-
Inhalation Technology for the 21st Century User friendly Breath actuated,
soft mist delivery system intuitive for use. -
Inhalation Technology for the 21st Century Improved Compliance
Soft Mist.
About us
About us
Omega Life Science Ltd. Is a privately held Israeli medical device and specialty biomed company established in 2011. The company develops unique aerosol generation technologies for soft-mist-inhalers and other drug delivery systems. Our unique technologies are geared towards providing simple, robust, user-friendly and disposable devices that can operate as both an inhaler and nebulizer capable of generating soft-mist aerosol with low MMAD (below 2 microns) and high fine particle fraction. Our technologies include novel pneumatic, mechanical and thermal platforms designed for pharmaceutical as well as wellness applications.
The company’s head offices and laboratory are located at Migdal Haemeq Industrial Park, Israel, employing a team of twelve professionals, four of whom are PhD level, working full time and boasts an advisory board consisting of renowned physicians and pharmacologists.
Our laboratory is equipped with state-of-the art equipment for formulation and aerosol characterization and runs in a GLP-like manner utilizing a unique tailor-made computerized quality control system.
The company received an ISO 13485 certification for design and development of medical device in December 2017.
Mission
To become a leading global provider of novel inhalation drug delivery systems.
The company will pursue the development of innovative inhalable therapeutics intended for a broad range of clinical needs, and hold a significant share of the respiratory therapy market by providing a range of proprietary pharmaceutical products
Vision
A world in which inhalation is the preferred route of administration for systemic medications, where respiratory diseases are treated with high rates of success through easy-to-use and effective inhalable medications, resulting in high therapy compliance and adherence.
Key Management
Yair Weinberger
COB
Mr. Yair Weinberger is the owner and president of Electrotherm Group, a group of companies headquartered in Israel, a worldwide expert in the development and manufacturing of thermal process equipment for the aviation industry.
Asaf Weinberger
CEO
Mr. Asaf Weinberger (MBA) is a mechanical engineer (B.Sc.) graduate of the Technion. He served as an engineering officer (captain) in the Israeli Defense Force (IDF), and later as sales development engineer on behalf of the Israeli Aircraft Industries in Southeast Asia.
Dr. Miron Hazani
CTO
Dr. Hazani holds a Ph.D. in Biochemistry from Tel Aviv University, and trained in chemical physics and nanotechnology at the Weizmann Institute of Science. He held senior R&D positions in leading companies in the fields of nanotechnology.
Dr. Manfred Keller
Director of New Products Strategy (Advisory Board)
Served for 11 years as Chief Scientific Officer and Exec. VP with PARI Pharma, Germany, a global leader in inhalation products. Prior to that he spent 12 years as Head of aerosols and inhalation with SkyePharma /JAGO, Switzerland. Previously, served as Head of product development and pharmaceuticals with Ratiopharm, Germany. He holds a Ph.D. in Pharmacology from Freiburg University, Germany.
Dr. Jean-Philippe Selles
Director of Pharmaceutical Operations (Advisory Board)
Held senior positions in a number of leading pharmaceutical companies and has vast experience in development strategies, scientific and regulatory affairs, alliances and mergers, and fund raising. He holds a Ph.D. in Biopharmacy and Pharmaceutical Sciences, and a Pharm. D. from the University of Montpellier, France.
Mr. Bill Morachnick
Director (Nicogen)
An experienced Chief Executive Officer with a demonstrated history of generating outstanding business results throughout the world and across a broad range of industries. Recently, led the sale of SFRTI GmbH to Japan Tobacco Group (JTG) for a $5 billion all-cash acquisition, after founding the company and managing its rapid growth from start (2007) until acquisition (January 2016). Mr. Morachnick serves as advisor to management and as a director in Nicogen.